{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:49:56Z","timestamp":1791953396164,"version":"4.3.4"},"reference-count":18,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>Historically, there has been considerable delay between stringent regulatory authority approval for new TB drugs in adults, and subsequent trials, registration, and access for children. This has been due to the exclusion of older children from phase 3 trials, the failure to study novel drugs in younger children earlier on, and delays in developing and testing paediatric formulations. Specific barriers include the failure to develop paediatric investigational plans early on, regulatory barriers, inefficient trial design and implementation, limited site capacity, and lack of advocacy and funding. The successful implementation of paediatric clinical trials depend on timely access to appropriate paediatric formulations. We review the delayed evaluation of rifapentine in children and describe barriers, costs in time and resources, and lost opportunities resulting in delayed clinical trials and access in the field, and highlight avoidable delays. Lessons regarding enablers and inhibitors from the rifapentine experience could prevent similar delays in future.<\/jats:p>","DOI":"10.5588\/ijtldopen.26.0263","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:28:16Z","timestamp":1791952096000},"page":"611-617","source":"Crossref","is-referenced-by-count":0,"title":["Trials, tribulations, and formulations in access to new TB drugs for children: learning from rifapentine"],"prefix":"10.5588","volume":"3","author":[{"given":"A.C.","family":"Hesseling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Salazar-Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Louey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Penazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garcia-Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tarlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101321280886000_3.10.611.1","unstructured":"Treatment Action Group . 2024 report on TB research funding trends. New York, NY: TAG, 2024."},{"key":"2026101321280886000_3.10.611.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"issue":"3","key":"2026101321280886000_3.10.611.3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2026101321280886000_3.10.611.4","doi-asserted-by":"crossref","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 1: prevention \u2013 tuberculosis preventive treatment. Geneva: WHO, 2020.","DOI":"10.30978\/TB2021-2-86"},{"key":"2026101321280886000_3.10.611.5","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pit077"},{"key":"2026101321280886000_3.10.611.6","unstructured":"World Health Organization . WHO operational handbook on tuberculosis: module 1: prevention - tuberculosis preventive treatment. 2nd ed. Geneva: World Health Organization, 2024."},{"key":"2026101321280886000_3.10.611.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"2026101321280886000_3.10.611.8","unstructured":"Mathad JS . DOLPHIN-Moms: pharmacokinetics and HIV suppression with once-daily dolutegravir and 3 HP in pregnancy. The Conference on Retroviruses and Opportunistic Infections (CROI), New York, NY, 2026, abstract no. 147. https:\/\/www.croiconference.org\/abstract\/3660-2025\/."},{"key":"2026101321280886000_3.10.611.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105938"},{"issue":"1","key":"2026101321280886000_3.10.611.10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5588\/ijtldopen.24.0250","article-title":"Children and providers\u2019 perspectives on once-weekly rifapentine and isoniazid TB preventive therapy","volume":"2","author":"Marthinus","year":"2025","journal-title":"IJTLD Open"},{"key":"2026101321280886000_3.10.611.11","unstructured":"World Health Organization . Prequalication of medical products. Update on nitrosamine impurities 29 October, 2025. Geneva: World Health Organization, 2025. https:\/\/extranet.who.int\/prequal\/news\/update-n-nitrosamine-impurities."},{"key":"2026101321280886000_3.10.611.12","unstructured":"Treatment Action Group . Isoniazid\/rifapentine (3HP) access roadmap and patent landscape. New York, NY: Treatment Action Group, 2020. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2020\/03\/3hp_access_roadmap_and_patent_landscape.pdf."},{"key":"2026101321280886000_3.10.611.13","unstructured":"Treatment Action Group . Letter to Sanofi. New York, NY: Treatment Action Group, 2020. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2020\/08\/TAG_OTMeds_letter_sanofi_patent_withdrawals_8_3_20.pdf."},{"key":"2026101321280886000_3.10.611.14","unstructured":"World Health Organization . Paediatric drug optimization for tuberculosis meeting report. Geneva: World Health Organization, 2023."},{"issue":"4","key":"2026101321280886000_3.10.611.15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5588\/ijtldopen.24.0546","article-title":"Children\u2019s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations","volume":"2","author":"Hoddinott","year":"2025","journal-title":"IJTLD Open"},{"key":"2026101321280886000_3.10.611.16","unstructured":"World Health Organization . Global tuberculosis report. Geneva: World Health Organization, 2025."},{"key":"2026101321280886000_3.10.611.17","unstructured":"ICH harmonised tripartite guideline . Pharmaceutical development. Geneva: World Health Organization, 2009. https:\/\/database.ich.org\/sites\/default\/files\/Q8%28R2%29%20Guideline.pdf."},{"key":"2026101321280886000_3.10.611.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00007-9"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.26.0263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:28:19Z","timestamp":1791952099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.26.0263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.5588\/ijtldopen.26.0263"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.26.0263","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}